Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers

Biomaterials

Volumn 32, Issue 21, 2011, Pages 4840-4848

  Bachar, Gideon ^a   Cohen, Keren ^a   Hod, Roy ^a   Feinmesser, Raphael ^a   Mizrachi, Aviram ^a   Shpitzer, Thomas ^a   Katz, Odelia ^a   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

CD44; Head and neck cancers; Hyaluronan; Nanomedicine

Indexed keywords

ANGIOGENESIS; ANTI-CANCER AGENTS; CANCEROUS CELLS; CD44; CELL SURFACE RECEPTORS; CHEMORADIATION; ENCAPSULATION EFFICIENCY; EX-VIVO; HEAD-AND-NECK CANCER; HYALURONAN; INSOLUBLE DRUG; MITOMYCIN C; MOUSE TUMORS; NANOMEDICINES; PACLITAXEL; PARTICLE CLUSTERS; THERAPEUTIC EFFECTS;

CELL MEMBRANES; CELL PROLIFERATION; ENCAPSULATION; MEDICAL NANOTECHNOLOGY; PATIENT TREATMENT; TUMORS;

DISEASES;

HERMES ANTIGEN; HYALURONIC ACID; MITOMYCIN C;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; EX VIVO STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NANOPHARMACEUTICS; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG CARRIERS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYALURONIC ACID; MALE; MATERIALS TESTING; MICE; MIDDLE AGED; MITOMYCIN; NANOSTRUCTURES; PACLITAXEL; PARTICLE SIZE;

EID: 79955761548     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.03.040     Document Type: Article

References (43)

1. Assimakopoulos D., Kolettas E., Patrikakos G., Evangelou A. The role of CD44 in the development and prognosis of head and neck squamous cell carcinomas. Histol Histopathol 2002, 17(4):1269-1281.
2. Wang S.J., Wong G., de Heer A.M., Xia W., Bourguignon L.Y. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009, 119(8):1518-1530.
3. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 p.oteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14(2):163-176.
4. DeGrendele H.C., Estess P., Siegelman M.H. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997, 278(5338):672-675.
5. Taher T.E., Smit L., Griffioen A.W., Schilder-Tol E.J., Borst J., Pals S.T. Signaling through CD44 is mediated by tyrosine kinases. Association with p56lck in T lymphocytes. J Biol Chem 1996, 271(5):2863-2867.
6. Naor D., Sionov R.V., Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997, 71:241-319.
7. Naor D., Nedvetzki S., Golan I., Melnik L., Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci 2002, 39(6):527-579.
8. Ogino S., Nishida N., Umemoto R., Suzuki M., Takeda M., Terasawa H., et al. Two-state conformations in the hyaluronan-binding domain regulate CD44 adhesiveness under flow condition. Structure 2010, 18(5):649-656.
9. Ponta H., Sherman L., Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4(1):33-45.
10. Lesley J., Hyman R., Kincade P.W. CD44 and its interaction with extracellular matrix. Adv Immunol 1993, 54:271-335.
11. Skelton T.P., Zeng C., Nocks A., Stamenkovic I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol 1998, 140(2):431-446.
12. Wang S.J., Wreesmann V.B., Bourguignon L.Y. Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck 2007, 29(6):550-558.
13. Wang S.J., Bourguignon L.Y. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006, 132(7):771-778.
14. Zeng C., Toole B.P., Kinney S.D., Kuo J.W., Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 1998, 77(3):396-401.
15. Horner M.J., Ries L.A.G., Krapcho M., Neyman N., Aminou R. Howlader N ea. SEER cancer statistics review 1975-2006, National Cancer Institute., posted to the SEER web site 2009.
16. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998, 83(12):2638-2648. [see commetns].
17. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97(5):418-428.
18. Kloos R.T., Eng C., Evans D.B., Francis G.L., Gagel R.F., Gharib H., et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19(6):565-612.
19. American cancer society cancer facts & figures 2010 2010, Society Ac, Atlanta American Cancer Society, 2010.
20. Hinoshita E., Uchiumi T., Taguchi K., Kinukawa N., Tsuneyoshi M., Maehara Y., et al. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 2000, 6(6):2401-2407.
21. Dalton J.T., Wientjes M.G., Badalament R.A., Drago J.R., Au J.L. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 1991, 51(19):5144-5152.
22. Peer D., Margalit R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 2004, 108(5):780-789.
23. Rivkin I., Cohen K., Koffler J., Melikhov D., Peer D., Margalit R. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 2010, 31(27):7106-7114.
24. Yuspa S.H., Morgan D., Lichti U., Spangler E.F., Michael D., Kilkenny A., et al. Cultivation and characterization of cells derived from mouse skin papillomas induced by an initiation-promotion protocol. Carcinogenesis 1986, 7(6):949-958.
25. Peer D., Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 2004, 6(4):343-353.
26. Peer D., Florentin A., Margalit R. Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim Biophys Acta 2003, 1612(1):76-82.
27. Youns M., Fu Y.J., Zu Y.G., Kramer A., Konkimalla V.B., Radlwimmer B., et al. Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics. Naunyn Schmiedebergs Arch Pharmacol 2010, 382(3):221-234.
28. Platt V.M., Szoka F.C. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008, 5(4):474-486.
29. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2(12):751-760.
30. Kedmi R., Ben-Arie N., Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of toll-like receptor 4 in immune activation. Biomaterials 2010, 31(26):6867-6875.
31. Wallach-Dayan S.B., Grabovsky V., Moll J., Sleeman J., Herrlich P., Alon R., et al. CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. J Cell Sci 2001, 114(Pt 19):3463-3477.
32. Salles G., Zain M., Jiang W.M., Boussiotis V.A., Shipp M.A. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 1993, 82(12):3539-3547.
33. Kuniyasu H., Oue N., Tsutsumi M., Tahara E., Yasui W. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. Clin Cancer Res 2001, 7(12):4067-4072.
34. Kuhn S., Koch M., Nubel T., Ladwein M., Antolovic D., Klingbeil P., et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 2007, 5(6):553-567.
35. Iida N., Bourguignon L.Y. New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995, 162(1):127-133.
36. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65(1):13-24.
37. Li F., Tiede B., Massague J., Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007, 17(1):3-14.
38. Sillanpaa S., Anttila M.A., Voutilainen K., Tammi R.H., Tammi M.I., Saarikoski S.V., et al. CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res 2003, 9(14):5318-5324.
39. Bradner W.T. Mitomycin C: a clinical update. Cancer Treat Rev 2001, 27(1):35-50.
40. Haffty B.G., Son Y.H., Papac R., Sasaki C.T., Weissberg J.B., Fischer D., et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the yale mitomycin randomized trials. J Clin Oncol 1997, 15(1):268-276.
41. Abitbol A.A., Sridhar K.S., Lewin A.A., Schwade J.G., Raub W., Wolfson A., et al. Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. Cancer 1997, 80(2):266-276.
42. Peer D., Margalit R. Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes. Arch Biochem Biophys 2000, 383(2):185-190.
43. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53(2):283-318.